The FDA has cleared an investigational new drug application for A197, which is being evaluated for the treatment of dry eye disease, according to a press release from Aramis Biosciences.
“We are pleased that FDA has cleared A197 to move into phase 2 clinical trials in dry eye patients. We believe that A197, with its novel mechanism of action targeting the immunopathogenesis of the disease and clean tolerability profile, has the potential to significantly improve the standard of care in dry eye disease,” David S. Tierney, MD, president and CEO (Read more...)